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Derangements in acetylcholine metabolism in brain synaptosomes in
chronic renal failure. Chronic renal failure causes abnormalities in the
central nervous system function and in norepinephrine metabolism of
brain synaptosomes. The present study examined the effect of renal
failure on the metabolism of another neurotransmitter, acetylcholine,
which is involved in the modulation of behavioral and motor function.
We measured acetylcholine content and release, choline content,
uptake and release and activity of choline kinase in synaptosomes from
rats with renal failure with various duration, renal failure-parathyroid-
ectomized rats maintained normocalcemic, renal failure and normal rats
treated with verapamil. Acetylcholine content increased while choline
content decreased proportionally and significantly (P < 0.01) with the
duration of renal failure; choline kinase activity was reduced (P <0.01).
These derangements were prevented by parathyroidectomy of renal
failure rats or by their treatment with verapamil. Choline uptake and
release were elevated in renal failure and these abnormalities were not
corrected by parathyroidectomy or verapamil therapy. Acetylcholine
release was elevated in renal failure and parathyroidectomy prevented
this derangement. Verapamil reduced acetylcholine release in both
normal and renal failure rats. The data show that: (a) renal failure
causes significant derangements in acetylcholine metabolism leading to
its accumulation in and an increase in its release from brain synapto-
somes; (b) this is mainly due to reduced activity of choline kinase, most
likely, mediated by the state of secondary hyperparathyroidism of renal
failure; (c) blocking the parathyroid hormone-induced calcium influx
into synaptosomes by verapamil prevented the abnormalities in acetyl-
choline metabolism; and (d) the derangement in choline uptake and
release in CRF is not related to excess parathyroid hormone since
parathyroidectomy or verapamil treatment did not correct them.
Many investigators have provided data consistent with the
notion that elevated blood levels of PTH in chronic renal failure
adversely affect the function of the central nervous system [1,
2]. These data led to the proposition that PTH may act as a
neurotoxin when its blood levels are elevated [3].
This effect of excess PTH was attributed to the ability of the
hormone to enhance entry of calcium into the brain. Indeed,
chronic exposure to excess VFH in the presence or absence of
CRF is associated with increased brain content of calcium [1, 3]
and in elevation of the basal levels of cytosolic calcium
([Ca2]i) of brain synaptosomes [4].
The elevation in [Ca2]i of brain synaptosomes was associ-
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ated with marked derangement in their metabolism. These
synaptosomes display a decrease in their ATP content [4], a
reduction in the Vmax of Ca2 ATPase [5] and Na-K ATPase
[6], a decrease in norepinephrine content, release and uptake
[7], alteration in the activity of tyrosine hydroxylase and
monoamine oxidase [8], and reduction in their phospholipid
contents [9]. All these abnormalities are prevented by prior
PTX of CRF rats or by their treatment with a verapamil [4—9].
Both of these procedures normalized the levels of synapto-
somes [Ca2]i [4].
The neural mechanisms of behavior and of motor function are
affected by the cholinergic system [10]. Indeed, Parkinson like
tremors and dyskinetic movement could be precipitated by
centrally active cholinergic agonists. CRF is associated with
behavioral abnormalities and motor dysfunction [11]. It is
possible that these derangements are at least in part, due to an
effect of CRF on acetylcholine metabolism in brain and that
such an effect of CRF is mediated by the state of secondary
hyperparathyroidism. The present study examined this postu-
late by evaluating acetyicholine metabolism of brain synapto-
somes.
Methods
Male Sprague-Dawley rats weighing 250 to 400 g were stud-
ied. A total of 250 rats were used, they were fed chow diet
(Wayne Research Animal Diets, Chicago, Illinois, USA)
throughout the study and allowed to drink ad libitum. The diet
contained 1.4% calcium and 0.97% phosphorus. Ten groups of
animals were studied including: (a) normal rats; (b) rats with
chronic renal failure (CRF) for three weeks, six weeks, or 12
weeks; (c) normocalcemic parathyroidectomized rats with CRF
(CRF-PTX) for three weeks or six weeks; (d) normal rats
treated with verapamil (normal-V) for three weeks or six weeks;
(e) rats with CRF for three weeks, or six weeks treated with
verapamil (CRF-V). The rats were assigned randomly to these
various groups.
Parathyroidectomy was done by electrocautery, and the
success of the procedure was ascertained by a decrease in the
plasma levels of calcium of at least 2 mgldl. The PTX rats were
allowed to drink freely water containing 50 gfliter of calcium
gluconate. This procedure is adequate to normalize plasma
calcium in PTX rats. Animals that did not display a fall in
plasma calcium of 2 mgldl or more after PTX and PTX rats that
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Table I. Biochemical data in the various groups of animals
did not attain normocalcemia with the drinking of calcium-
containing water were discarded and not used in the study.
Seven days after PTX, the animals underwent right partial
nephrectomy through a flank incision; a week later a left
nephrectomy was performed. This nephrectomy procedure was
also performed in rats with intact parathyroid glands. Vera-
pamil (Isoptin, Knoll AG, Ludwigshafen, Germany) was in-
jected subcutaneously in a dose of 0.1 p.g/g body weight twice
daily. The normal rats received subcutaneous injection of
vehicle only.
Two days before sacrifice, the rats were housed in metabolic
cages for the collection of two consecutive 24-hour urine output
for the measurements of creatinine clearance. On the day of the
study, the rats were sacrificed by decapitation, and blood was
collected for the measurements of creatinine, calcium, phos-
somes were prepared as reported previously by us [61. The
details of the procedure for the isolation of synaptosomes, as
well as the various approaches to evaluate the intactness of the
synaptosomes, their viability, and the degree of contamination
with mitochondria and endoplasmic reticulum, have been pre-
viously reported from our laboratory [6, 8]. Each forebrain
yielded synaptosomes containing 7 to 10 mg protein which was
diluted in 1.5 to 2.0 ml of the isolation media. Protein was
measured by the method of Lowry et a! [12].
Acetylcholine (ACh) and choline content of brain synapto-
somes were measured with chemiluminescence method de-
scribed by Israel and Lesbats [13] with minor modification. This
procedure is based on the hydrolysis of ACh by acetylcholines-
terase and on the convertion of choline to betadine and H202 by
choline oxidase, which generates a light emission in the pres-
ence of luminol and peroxidase. Aliquots of 0.25 ml of synap-
tosomal suspension (1.2 to 2.0mg protein) were treated with 0.5
ml 10% TCA, sonicated and kept on ice for 15 minutes. After
centrifugation with Sorval RC-5 refrigerated centrifuge (DuPont
Co. Instrument Product Division, Newton, Connecticut, USA)
at 9,800 g x io mm, the supernatant was saved and washed with
water saturated ether until pH 4 was reached. The residues of
BodyN weight g Calcium Phosphorus
Plasma levels mg/di
Creatinine
Creatinine
clearance
pJ/min/100 g
Serum
PTH
pg/rn!
Normal 40 318 4.1 9,7 0.1 6.6 0.18 0.32 0.10 536 16.2 18 1.3
3 Week studies
CRF 30 324 10.0 9.8 0.1 6.2 0.13 1.11 0.06 147 12.0 39.2 4.8a
CRF-PTX 21 352 8.7 9.2 0.2 6.0 0.16 1.01 0.05k 136 7.6a 20.6 2.2
Normal-V 30 298 7.3 9.2 0.1 6.6 0.15 0.39 0.02 453 14.0
CRF-V 27 348 6.3 9.4 0.2 6.4 0.3a 1.0 0.lOa 149 7,9a 44.8 5.6a
6 Week studies
CRF 20 354 10 9.9 0,1 6.8 0.19 1.05 0.03a 153 74 65.1 6.6a
CRF-PTX 15 331 15.5 9.2 0.2 6.3 0.20 0.99 0.04a 160 8.5 14.6 3.8
Normal-V 15 372 6,9 9.3 0.1 6.6 0.21 0.38 0.02 454 12.1 13.0 0.5
CRF-V 16 367 7.7 9.2 0.2 6.4 0.18 0.98 0.03a 165 7,7a 55.0 4.
12 Week studies
CRF 14 383 5.7 9.2 0.2 6.3 0.13 1.15 0.05a 124 74 64.7 9,5a
Data are presented in mean SE.
a P < 0.01 vs. other groups
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Fig. 1. Standard curve for acelyicholine as measured by high emission
intigrated and expressed as F value. Each datum point represents the
mean of 6 studies and brackets denote I SE.
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Fig. 2. The relationship between the synaptosoma! content of ACh (•)
or choline (0) with the duration of CRF. Each datum point represents
the mean of 10 to 13 rats for ACh and 8 to 12 for choline and brackets
denote 1 SE.
phorus and parathyroid hormone (PTH). ether were removed by nitrogen gas. The sample was subse-
Cerebral cortices were dissected from brains and synapto- quently oxidized for at least 30 minutes by addition of 35 d of
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Fig. 3. ACh content of brain synapsosomes obtained from the various
groups of animal. Each column represents the mean of 7 to 13 (3
weeks), and 7 to 10 (6 weeks) rats and brackets denote 1 SE. Symbols
are: (D) normal; (•) CRF; () CRF-PTX; () CRF-V; (DIII) normal-V.
* P < 0.01 versus other groups.
0.5% (wt/vol) K103. For the measurement of chemilumines-
cence, 200 d reaction cocktail buffer (containing 100 1.d choline
oxidase (250 U/mi), 50 d peroxidase (2 mg/mi) and 100 l
luminol (1 mM) in 2.5 ml 0.2 M sodium phosphate buffer with 50
mM NaCI stirred 20 mm) was put into the test chamber of LAD
535 luminometer (Turner Design, Sunnyvale, California, USA).
Then 50 j.d sample of the synaptosomes extract was added and
light emission, due to choline oxidation was measured. After
this light emission decayed, 50 pmoll5o p1 choline standard was
added and light emission was measured again. To measure
ACh, 50 p1 acetylcholinesterase (10,000 U/mi) was added
instead of choline standard and after the new chemilumines-
cence decayed, 8 pmolISO p1 ACh standard was added and
chemiluminescence was measured again. The chemilumines-
cence readings before and after the addition of standards were
Fig. 4. Choline content of brain synaptosomes obtained from the
various groups of animals. Each column represents the mean of 6 to 8
rats and brackets denote I SE. Symbols are: (U) normal; (•) CRF;() CRF-PTX; () CRF-V; (Q) normal-V. * P < 0.01 versus other
groups.
used to calculate the choline and ACh content. Acetylcholines-
terase was purified by the method detailed by Israel and
Lesbats [13]. In our hands the light emission was linearly
proportional to ACh concentration in the range of 8 to 20
pmoll5o p1 (Fig. 1).
ACh and choline release were measured according to the
method of Willoughby, Harvey and Clark [14]. Aliquots of 250
p1 of freshly prepared synaptosomes were incubated in the
Krebs-Henseleit (KHBS) saline (136 mr't NaCI, 5.5 mM KC1,
1.2 mrs MgCI2, 16.2 mM NaHCO3, 1.2 mti NaH2PO4, 10 m Na
Hepes, pH 7.4) with 12.5 p.M phospholine for 10 minutes at 4°C
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N
Acetyicholme release pmol1mg protein
5 mm 15 mm 30 mm
Normal
CRF
CRF-PTX
Normal-V
CRF-V
11
8
6
8
9
42 6.5
61 47a
48 2.3
16 4.1"
17 4.8"
55 6.4
84 8.7a
57 3.4
31 8.4"
26 74b
74 5.5
115 5.0
74 5.3
44 6.8"
51 6.1"
to inhibit acetylcholinesterase. Excess of phospholine was then
removed by centrifugation with Sorval RC-5 refrigerated cen-
trifuge at 9800 g x 10 mm and by washing of the pellet three
times with 0.9% NaC1. Release of ACh and choline was
obtained by incubation of the sample with 1 ml KHBS solution
containing in addition 2.2 mri CaCI1, 1 mri glucose and 35 mM
KC1 for 5, 15 and 30 minutes at 37°C water shaking bath. The
medium was separated from synaptosomes by centrifugation
and its ACh and choline content were measured by chemilumi-
nescence as described above.
Choline kinase activity was determined by the method of
Wecker and Reinhardt [15]. Aliquots of 50 l freshly prepared
synaptosomal suspension were incubated with 0.45 ml phos-
phate buffer (124 mrvi NaCI, 4.75 mri KCI, 0.75 mM CaCl2, 1.3
mM MgSO,,, 2.0 mri NaH2PO4, 8.0 mM Na2HPO4, 11.1 mM
glucose, pH 7.5) containing 25 /.LM choline and 0.4 tCi 3H
choline for 10 minutes at 37°C in a shaking water bath. Back-
ground sample was kept on ice for the same time. The pellet
was separated by centrifugation with Sorval RC-5 refrigerated
centrifuge at 9,800 g for 10 minutes, washed with phosphate
buffer medium and shocked with 70 l of 0.01 M HCI. [3H]
phosphorycholine was isolated by adding 150 1.d solution of
tetraphenylboron in butyronitrile (30 mg/ml). The sample was
vortexed, spined in Beckman microcentrifuge to separate the
organic and water phases, and the organic layer was discarded.
The extraction procedure was repeated three times. Radioac-
tivity in the aqueous layer was measured by Beckman LS-7000
scintillation counter (Beckman Instruments Inc., Palo Alto,
California, USA). Choline kinase is expressed as pmol of
phosphorycholine produced/mg proteinllo mm.
Choline uptake was determined by the method of Wecker and
Reinhardt [15]. Aliquots of 50 1.d freshly prepared synapto-
somes were incubated for 10 minutes with [3H] choline as
described above. The reaction was stopped by centrifugation at
9,800 g x 10 mm. The pellet was resuspended with 0.5 ml
phosphate buffer and 250 1.d of it was laid on 50 d of silicon oil
(specific gravity 1.025 to 1.030) in a small centrifugation tube
and spined in Beckman microcentrifuge for 45 seconds. The tip
of the tube was cut out and used to measure radioactivity with
Beckman LS-7000 scintillation counter. The uptake value is
expressed as pmole choline/mg protein/mm.
Acetylcholine chloride, choline chloride, choline oxidase
(Alcaligenes spp.), horseradish peroxidase (type II), acetylcho-
linesterase (electric-eel type VI-S), luminol and tetraphenylbo-
ron were obtained from Sigma Chemical Co. (St. Louis, Mis-
souri, USA). Ether and butyronitrile were purchased from
Aldrich Chemical Co. [Methyl 3H} choline chloride (79.3 mCi!
mmol) was purchased from Amersham International. Phospho-
line was generously given by Ayerst Laboratories (New Jersey,
USA). All other chemicals were of the highest grade available
and all solutions were made up in double distilled water.
The measurement of calcium concentration in plasma was
made by Perkin-Elmer atomic absorption spectrophotometer,
Model 503 (Perkin Elmer Corp., Norwalk, Connecticut, USA),
Table 2. Acetylcholine release by brain synaptosomes in the various
groups of rats after 3 weeks of the experimental condition
A 3 Weeks
Data are presented as mean SE.
a P < 0.01 vs. all groups
b P < 0.01 vs. all groups
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Fig. 5. The activity of choline kinase of brain synaptosomes obtained
from the various groups of animals. Each column represents the mean
of 6 to 13 (3 weeks) and 6 to 15 (6 weeks) rats and the brackets denote
1 SE. Symbols are: () normal; (U) CRF; () CRF-PTX; () CRF-V;() normal-V. * P < 0.01 versus all groups.
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Table 3. Choline uptake by brain synaptosomes of various groups of rats
Choline uptake pmol/mg protein/JO mm
Normal CRF CRF-PTX Normal-V CRF-V
115 6.1 (12)
3 Weeks 167 8.5 (9) 154 7,3a (6) 113 6.1 (8) 167 17.9a (8)
6 Weeks 234 11.4" (9) 227 17.1" (6) 105 10.2 (7) 262 25.5" (6)
Data are presented as mean SE. Data in brackets represent the number of rats.
a P < 0.01 vs. normal
b p < 0.01 vs. normal and vs. 3 weeks
Table 4. Choline release by brain synaptosomes in the various
groups studied after 3 weeks of the experimental condition
N
Choline release pmo!/mg protein
5 mm 15mm 30mm
Normal II 67 17 337 40 948 152
CRF 8 570 60 1228 84 1990 190
CRF-PTX 6 504 6O 885 67 1884 90
Normal-V 8 76 11 458 49 1260 117
CRF-V 9 212 28b 898 l30 1740 13
a p < 0.01 vs. normal and normal-V
"P < 0,01 vs. all groups
P < 0.05 vs. CRF
and those of creatinine and phosphorus by Technicon autoan-
alyzer (Technicon Instrument Inc., Tarrytown, New York,
USA). Serum level of PTH was determined by INS-PTH
immunoassay kit (Nichols Institute Diagnostics, San Juan Cap-
istrano, California, USA). This assay recognizes the aminoter-
minal fragment of PTH. The lowest detectable level is 3 pg/mI,
the intraassay variation is 7.3% and the intraassay variation is
4%. Data are presented as mean SE. Statistical evaluation was
made with one-way analysis of variance and Tukey's HSD test
for multiple comparison between groups.
Results
Table 1 presents the biochemical data in the various group of
animals studied. There were small variations in the weights of
the animals among the various group studied, and the values of
the plasma concentrations of calcium and phosphorus were not
different. The nephrectomy procedure resulted in a significant
(P < 0.01) rise in the plasma concentrations of creatinine with
the values in CRF, CRF-PTX, and CRF-V animals being three
times higher than those in normal and normal-V rats. The
values of creatinine clearance in CRF, CRF-PTX, and CRF-V
rats were significantly (P < 0.01) lower than those in normal or
normal-V animals. The serum levels of PTH were significantly
(P < 0.01) elevated in CRF and CRF-V rats, PTX of CRF rats
prevented the rise in serum PTH levels.
The content of ACh of brain synaptosomes increased pro-
gressively with the duration of CRF. The values were signifi-
cantly (P < 0.01) higher than normal (39 1.2 pmollmg protein)
after three weeks (80 6.6 pmol/mg protein), six weeks (105
10.7 pmollmg protein) and 12 weeks (130 6.3 pmollmg
protein) of CRF (Fig. 2). These elevated levels of ACh in CRF
were prevented by prior PTX of the CRF rats or by their
treatment with verapamil. Indeed, three or six weeks CRF-PTX
rats or CRF-V rats have normal ACh content despite CRF (Fig.
3). Treatment of normal rats with verapamil did not cause a
significant change in the ACh content of their synaptosomes.
Choline content of brain synaptosomes after three weeks of
CRF (1.82 0.08 nmollmg protein) was significantly (P < 0.01)
lower than normal (2.3 0.11 nmollmg protein). The choline
content decreased further after six weeks of CRF to 1.43 0.15
nmol/mg protein and remained low at the end of 12 weeks ot'
CRF (1.38 0.06 nmollmg protein; Fig. 2). This abnormality
was prevented by PTX or verapamil treatment in both groups
with three or six weeks of CRF (Fig. 4). Treatment of normal
rats with verapamil did not affect the choline content of their
synaptosomes.
ACh release from brain synaptosomes was studied only after
three weeks of CRF. The data are presented in Table 2. ACh
release was significantly (P < 0.01) higher in CRF rats at all
time intervals studied. This abnormality was prevented by prior
PTX of the CRF rats. Indeed, the values of ACh release in
CRF-PTX rats were not different than those in normal rats. It is
of interest that verapamil treatment of normal rats produced a
significant decrease in ACh and the latter was not increased in
CRF-V rats. Indeed the values of ACh release in normal-V and
CRF-V animals were not different.
The data on choline uptake and release by brain synapto-
somes are depicted in Tables 3 and 4. Choline uptake in CRF
rats was significantly (P < 0.01) higher than in normal rats. The
values after six weeks of CRF were significantly (P < 0.01)
higher than those in rats with three weeks of CRF. Prior PTX or
treatment with verapamil did not prevent the rise in choline
uptake. Indeed the values in CRF, CRF-PTX or CRF-V were
not different both after three or six weeks of CRF. Treatment of
normal rats with verapamil did not affect the choline uptake by
their synaptosomes. Choline release was significantly (P <
0.01) elevated after three weeks of CRF. PTX of CRF rats or
their treatment with verapamil did not normalize choline re-
lease. The values at five minutes in CRF-V and at 15 minutes in
CRF-PTX were significantly (P <0.01) higher than normal but
lower than CRF rats. Treatment of normal rats with verapamil
did not affect choline release.
The activity of choline kinase of brain synaptosomes was
significantly (P < 0.01) lower in rats with three or six weeks of
CRF (15.7 1.46 and 18.7 1.36 pmollmg protein/b mm) than
in normal rats (25.9 1.45 pmollmg protein/b mm) (Fig. 5).
This abnormality was prevented by PTX of the CRF rats or by
their treatment with verapamil. Treatment of normal rats with
verapamil did not affect the activity of choline kinase.
Discussion
The results of the present study demonstrate that CRF is
associated with abnormalities in the metabolism of ACh of brain
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synaptosomes. These include increased choline uptake and
release, reduced choline content, impaired activity of choline
kinase and increased ACh content and release. The derange-
ments in ACh content and release, choline content and choline
kinase activity appear to be mediated by the state of secondary
hyperparathyroidism of CRF since prior PTX of the CRF rats
prevented these derangements.
We have previously shown that CRF causes a rise in basal
levels of [Ca2]i of brain synaptosomes [4] and this abnormality
is responsible for the derangements in their norepinephrine
metabolism [6] and phospholipids content [8]. Indeed, the
prevention of the rise in synaptosomal [Ca2]i of CRF rats by
PTX [4] was associated with normalization of their norepineph-
rine and phospholipid metabolism [6, 8]. Further support for
this notion is provided by the demonstration that treatment of
CRF rats with verapamil prevented the rise in synaptosomal
[Ca2]i [4] as well as the abnormalities in norepinephrine
metabolism [9] and phospholipids content [16]. The data of the
present study also show that treatment of CRF rats with
verapamil prevented the reduction in choline content, the rise in
ACh content and the impairment in the activity of choline
kinase. Our data are, therefore, consistent with the notion that
the majority of the derangements in ACh metabolism of brain
synaptosomes are, most likely, due to a rise in basal levels of
their [Ca2]i since the prevention of the latter event by PTX or
verapamil administration, normalized synaptosomal ACh me-
tabolism despite CRF.
Increased calcium burden of cells has been associated with
inhibition of many enzyme systems such as acetylcarnitine
transferase of myocardium [17], Na-K ATPase [18] and Ca2
ATPase of pancreatic islets and of brain synaptosomes [5, 6],
and tyrosine hydroxylase of brain synaptosomes [7]. It is,
therefore, plausible to propose that a rise in [Ca2]i of brain
synaptosomes in CRF [4] is responsible for the reduced activity
of their choline kinase. Indeed, an increase in calcium concen-
tration inhibits synthesis of phosphorycholine subsequent to
choline transport into brain synaptosomes; the phenomenon
appears to be due to inhibition of choline kinase [19]. This
enzyme is an important factor in the regulation of choline pool
in the brain since it phosphorylates choline to phosphorycholine
in a process that requires ATP [20]. The inhibition of choline
kinase in CRF as shown in our study and reduced ATP content
in synaptosomes in CRF [41, would, therefore, divert more
choline for the synthesis of ACh and consequently lead to the
rise in synaptosomal ACh content. Another factor that could
augment ACh content of synaptosomes in CRF is the increase
in choline uptake. However, this does not appear to play an
important role in the increase in synaptosomal content of ACh
in CRF, since in CRF-PTX and in CRF-V rats ACh content is
normal despite the presence of high choline uptake.
The mechanisms responsible for the increased ACh release
by synaptosomes from CRF rats with elevated blood levels of
PTH are not fully understood. Several possibilities should be
considered. First, during depolarization of the synaptosomes
both ACh and ATP are released simultaneously with a ratio of
AChIATP ranging 2.3:1 to 10.8:1 with mean value of 5.6:1 [21].
This does not necessarily mean that ACh release is dependent
on ATP content of synaptosomes; to our knowledge, there are
no data on the effect of reduced ATP content of synaptosomes
on their ACh release. However, one might expect that the
amount of ATP released is smaller during depolarization of the
synaptosomes with lower ATP content as in CRF. It is known
that the secreted ATP is hydrolyzed to generate adenosine and
the latter inhibits ACh release [22]. Therefore, with a poten-
tially smaller amount of ATP released by synaptosomes from
CRF animals, one would expect that the amount of adenosine
generated is also decreased. Under such circumstances ACh
release may be increased. Thus, one may propose that the low
ATP content of synaptosomes may, indeed, be associated with
augmented ACh release.
Second available data indicate that ACh release is affected by
the activity of Na-KATPase and inhibition of the latter is
associated with increased ACh release [23]. In CRF, the activ-
ity of synaptosomal Na-KATPase is reduced but it is normal
in CRF-P1'X and CRF-V rats [9]. It is possible that these
alterations in Na-KATPase activity are responsible, at least
in part, for our results on ACh release. It is also possible that
the increased ACh content of synaptosomes contributes to the
increase in its release. Our data cannot refute or prove this
possibility. One needs a model in which the ACh of synapto-
somes is increased without an inhibition of the activity of their
Na-KATPase. Studies of Ulus, Hirsch and Wurtman [24] in
adrenal medulla of rats suggested that an increase in ACh
content by feeding the animals choline was associated with
increased cholinergic transmission.
It is of interest that verapamil treatment of normal or CRF
rats caused a reduction in ACh release despite normal synap-
tosomal content of ACh. It is possible that verapamil may
completely block or partially reduces the calcium signal which
follows depolarization of the synaptosomes and hence inter-
feres with ACh release. In addition, verapamil also may block
sodium channels [25] and this may also affect ACh release.
It is very interesting that despite the increase in choline
uptake in CRF, the choline content of the synaptosomes is low.
It is possible that the increase in ACh synthesis and the
augmented choline release could account for this phenomenon.
It should be mentioned that in CRF-PTX and CRF-V choline
content of synaptosomes is normal despite high choline uptake.
In these rats, choline kinase activity and ACh content are
normal indicating that choline is phosphorylated and there is no
demand on the choline pool for ACh synthesis. In addition,
choline release remains elevated and probably balances the high
uptake. The net effect of these events would be normal choline
content.
Another finding in our study that deserves a comment is the
high choline uptake in CRF which is not normalized in CRF-
PTX or CRF-V rats. This observation indicates that the ele-
vated synaptosomal choline uptake is not due to the state of
secondary hyperparathyroidism but is caused by other conse-
quences of CRF. The nature of these processes and the mech-
anisms responsible for increased choline uptake in CRF are not
evident. Augmented choline uptake was also reported in eryth-
rocytes of patients with CRF [26, 27]. Fervenza et a! [26] found
that both the Vmax and the Km for erythrocytes choline trans-
port were higher in CRF. They suggested that changes in the
characteristics of the individual transporters for choline occur
in CRF.
Choline transport into synaptosomes is mediated by two
processes [28, 29]. The first is sodium dependent, carrier
mediated, saturable and has high affinity with Km for choline in
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the range of 5 ELM. The second has a low affinity with Km for
choline of 40 to 80 M. It has been reported that blood levels of
choline in CRF patients are elevated [30] and this could
contribute to high choline uptake by erythrocytes and possibly
by brain synaptosomes. In our studies, we used 25 tM of
choline during the studies of choline uptake. This concentration
is in the range of that seen in blood of CRF patients [30].
Despite this high concentration of choline, its uptake by normal
synaptosomes was significantly lower than that by synapto-
somes from CRF animals. This observation suggests that the
characteristics of the low-affinity choline transport system of
brain synaptosomes are altered in CRF.
Choline uptake by brain synaptosomes is also influenced by
ACh release [31]. An increase in ACh release is associated with
rise in choline uptake. However, this phenomenon could not
explain our finding of increase choline uptake in CRF since
choline uptake remained elevated in CRF-PTX rats which have
normal ACh release.
Choline release is not regulated by the activity of Nat-
KATPase, is not calcium dependents, and is not affected by
KCN [14]. These observations indicate that choline release is
not regulated by processes that control ACh release. Our
results also show that ACh release was normal in CRF-PTX and
low in CRF-V at a time when choline release was elevated. The
mechanism responsible for the increase choline release in CRF
remained undefined.
Available data indicate that the cholinergic system plays a
major role in both behavior and motor function [10]. It has been
shown that increased cholinergic activity is associated with
arousal [32, 33], and may therefore lead to insomnia. Parkinson-
like tremor and dyskinetic movements have been produced by
centrally active cholinergic agents [34]. Finally, topical appli-
cation of ACh to cerebral cortex increased cerebral excitability
and caused convulsions [35, 36]. Therefore, one may propose
that the tremor, insomnia and seizures frequently encountered
in CRF are, at least partly, due to the increased ACh content of
and release by synaptosomes.
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